Financial Performance - The company's operating revenue for Q1 2016 was ¥602,196,495.46, representing an increase of 11.59% compared to ¥539,660,480.23 in the same period last year[7] - The net profit attributable to shareholders for Q1 2016 was ¥8,278,332.14, up 21.57% from ¥6,809,452.86 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥7,597,878.58, reflecting a growth of 31.03% compared to ¥5,798,759.62 in the previous year[7] - The basic earnings per share for Q1 2016 was ¥0.0248, an increase of 21.57% from ¥0.0204 in the same quarter last year[7] - Operating profit increased by 37.51% to ¥11,657,556.77, driven by higher operating revenue[14] Assets and Shareholder Information - The total assets at the end of the reporting period were ¥2,043,392,930.52, which is a 5.43% increase from ¥1,938,191,885.92 at the end of the previous year[7] - The net assets attributable to shareholders at the end of the reporting period were ¥1,270,281,651.41, showing a slight increase of 0.39% from ¥1,265,350,094.02 at the end of the last year[7] - The total number of shareholders at the end of the reporting period was 30,116[10] - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., held 19.94% of the shares, amounting to 66,627,786 shares[10] Cash Flow and Financial Activities - The company reported a negative net cash flow from operating activities of ¥37,875,888.15, compared to a negative cash flow of ¥26,767,785.93 in the same period last year[7] - Cash and cash equivalents decreased by 35.07% to ¥146,920,292.83, primarily due to investments in the acquisition fund for the Yueshang industry[13] - The company reported a net cash outflow from operating activities of -¥37,875,888.15, an increase of -¥11,108,102.22 compared to the previous year[14] - Net cash flow from financing activities was ¥68,869,674.50, a significant increase compared to -¥559,999.98 in the previous year, primarily due to increased bank loans[14] Investments and Subsidiaries - The company plans to invest ¥100 million in the Yueshang industry acquisition fund, representing a 10% stake in the fund[16] - A new wholly-owned subsidiary, Shaoxing Zhenyuan Traditional Chinese Medicine Co., Ltd., was established with an investment of ¥20 million[16] Other Financial Metrics - Financial expenses improved by 80.33% to -¥106,173.01, mainly due to increased bank loans[14] - Other receivables increased by 81.55% to ¥16,615,282.41, mainly due to an increase in business reserve funds[13] - Available-for-sale financial assets rose by 86.64% to ¥194,827,500.00, attributed to investments in the Yueshang industry acquisition fund[13] Future Expectations - The company expects significant changes in net profit for the first half of 2016 compared to the same period last year[19]
浙江震元(000705) - 2016 Q1 - 季度财报